RHJA
EVH icon

Rice Hall James & Associates’s Evolent Health EVH Stock Holding History

Rice Hall James & Associates’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-119,166
Closed -$1.5M – 282
2019
Q1 		$1.5M Buy
+119,166
New +$1.89M 0.05% 226

Other funds holding EVH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Rice Hall James & Associates's EVH Position: Q2 2019 in Review

Rice Hall James & Associates sold out of Evolent Health (EVH) in Q2 2019, closing a stake of 119,166 shares — an estimated $1.5M sold.

Rice Hall James & Associates first reported a position in EVH in Q1 2019 and held it in 1 quarter. The position peaked at $1.5M in Q1 2019. 183 funds tracked by Wall St. Rank hold EVH as of Q2 2019.

  • Rice Hall James & Associates reported no remaining Evolent Health position as of Q2 2019 after selling out during the quarter.
  • Rice Hall James & Associates sold 119,166 Evolent Health shares in Q2 2019, an estimated $1.5M.
  • Rice Hall James & Associates first reported a position in Evolent Health in Q1 2019 and held it in 1 quarter.
  • Rice Hall James & Associates's Evolent Health position peaked at $1.5M in Q1 2019.
  • 183 funds tracked by Wall St. Rank held Evolent Health as of Q2 2019.

Based on Rice Hall James & Associates's 13F filing for Q2 2019, filed 1 Aug 2019.